Needham Remains a Hold on Aerie Pharma (AERI)

Needham analyst Serge Belanger maintained a Hold rating on Aerie Pharma (AERIResearch Report) today. The company’s shares opened today at $15.21.

Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Cytokinetics, and Aerie Pharma. According to TipRanks, Belanger has an average return of -5.0% and a 37.76% success rate on recommended stocks.

Currently, the analyst consensus on Aerie Pharma is a Hold with an average price target of $15.25.

See Insiders’ Hot Stocks on TipRanks >>

Based on Aerie Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $33.31 million and a GAAP net loss of $19.37 million. In comparison, last year the company earned a revenue of $27.19 million and had a GAAP net loss of $38.69 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.

Read More on AERI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More